Prevention of clinical and histological signs of proteolipid protein (PLP)‐induced experimental allergic encephalomyelitis (EAE) in mice by the water‐soluble carbon monoxide‐releasing molecule (CORM)‐A1
We have evaluated the effects of the carbon monoxide‐releasing molecule CORM‐A1 [Na2(BH3CO2); ALF421] on the development of relapsing–remitting experimental allergic encephalomyelitis (EAE) in SJL mice, an established model of multiple sclerosis (MS). The data show that the prolonged prophylactic administration of CORM‐A1 improves the clinical and histopathological signs of EAE, as shown by a reduced cumulative score, shorter duration and a lower cumulative incidence of the disease as well as milder inflammatory infiltrations of the spinal cords. This study suggests that the use of CORM‐A1 might represent a novel therapeutic strategy for the treatment of multiple sclerosis.